BASEL, Switzerland,
Feb. 15 /PRNewswire-FirstCall/ -
Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to
provide its shareholders additional details about the unsolicited
offer received on February 9, 2011.
The offer was received from Auric Pharma Science, a well
established company based out of Madrid,
Spain, that has been operating since 1972. The offer
provided is for the purchase of all the outstanding shares of MRES
at a price of $0.15 per share.
As announced this morning, management has deemed
it in the best interest of the Company to accept such an offer
based on the documents provided by Auric. However, there are
outstanding conditions that have yet to be met in order to complete
the due diligence. Such details should be addressed by end of the
day, on February 25, 2011.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright . 15 PR Newswire